- Botulinum toxin type A (Botox) for the treatment of focal spasticity, including the treatment of wrist and hand disability due to upper limb spasticity associated with stroke in adults.
- Dalteparin (Fragmin) for the extended treatment of symptomatic venous thromboembolism (VTE) and prevention of its recurrence in patients with solid tumours. Use is restricted to healthcare professionals experienced in the treatment of VTE.
- Exenatide (Byetta) for the treatment of type 2 diabetes mellitus in combination with metformin and a glitazone as a third-line pre-insulin treatment option.
- Pazopanib (Votrient) for use in the first-line treatment of advanced renal cell carcinoma.
- Sildenafil citrate injection (Revatio) for pulmonary arterial hypertension in patients who are currently prescribed oral sildenafil but who are temporarily unable to take oral medicine, but are otherwise clinically and haemodynamically stable. Use is restricted to cases where it is recommended by specialists in the Scottish Pulmonary Vascular Unit and from the Scottish Adult Congenital Cardiac Service.
The SMC rejected adapalene/benzoyl peroxide gel (Epiduo) for the treatment of acne vulgaris and vinflunine (Javlor) for advanced or metastatic transitional cell carcinoma of the urothelial tract on the grounds of insufficient value for money.